|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03441014v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Etude de phase II de l’association chemofree obinituzumab et idélalisib dans la maladie de Waldenström en rechute ou réfractaire : résultats de l’analyse intermédiaire, après la phase d’induction
C. Tomowiak
,
S. Chevret
,
S. Poulain
,
C. Herbaux
,
A. Perrot
et al.
40e Congrès de la Société Française d’Hématologie, Sep 2020, Paris, France. 26 (S4), pp.135, 2020, Hématologie
Conference poster
hal-02945874v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase
C. Tomowiak
,
K. Desseaux
,
S. Poulain
,
C. Herbaux
,
A. Perrot
et al.
61st Annual Meeting and Exposition of the American Society of Hematology, Dec 2019, Orlando, United States. pp.346
Conference papers
hal-02418223v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study
Laetitia Largeaud
,
Pascale Cornillet-Lefebvre
,
Jean-François Hamel
,
Pierre-Yves Dumas
,
Naïs Prade
et al.
Journal articles
hal-03623649v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|